Summary of the technology
Civilization diseases are defined as occurring globally, widespread diseases, and affects not only older people or adults, but also teenagers and even children. Treatment of most of them is difficult, slow and also very costly. The civilization diseases are: cardiovascular, respiratory, gastrointestinal, allergic and infectious diseases, diabetes, obesity, cancers and mental health problems. It is estimated that these diseases are the cause of more than 80% of all deaths (according to the World Health Organization). Each risk of developing one of the civilization diseases significantly increases the risk of developing another. Therefore it is so important to implement the pro-health politics, promotion of healthy lifestyle and an appropriate pharmacotherapy.
Unfortunately, the currently used pharmacological agents are affected by many disadvantages, which show the need for continuous search for drugs with greater efficacy and favorable safety profile. One of the possible strategies for development of innovative therapies is the identification of drug candidates that inhibit the activity of phosphatases, the enzymes responsible for the course of many reactions in the body.
The phosphatases inhibit the activity of many cellular proteins, which is one of the basic regulatory mechanisms of the cells. They influence the regulation of numerous signal transduction pathways that determine basic functions of cells, including metabolism, cells division and their death by apoptosis. These mechanisms are also responsible for the formation, development and the course of many disorders and diseases. Thus, modulation of them may be an effective preventive and therapeutic strategy.
Description of the technology
The subject of the offer are new vanadium complexes with hydrazide-hydrazones as inhibitors of phosphatases and their use in the prevention and treatment of civilization diseases. The major application of the invention is diabetes, while other possible applications are civilization diseases such as cancers, neurodegenerative and cardiovascular diseases.
The subject of the offer are new complexes of vanadium (III, IV and V) with hydrazide-hydrazones and their compositions with ligands, that are of potential use in the prevention and treatment of many disorders and diseases. The presented compounds inhibit the activity of different phosphatases, which in consequence leads to several changes in the functioning of the regulatory mechanisms of the cells. The appropriate modification of these processes may provide new approaches to cancer, diabetes, cardiovascular and neurological diseases treatment.
Main advantages of its use
- The major advantages of the offered complexes are: • high-performance method of complexes synthesis, which can be carried out both under anaerobic conditions and in air atmosphere; • the possibility of use in the prevention and treatment of many disorders and diseases; • a wide range of potential routes of administration - oral, injectable, subcutaneous and inhalation.
- The vanadium project is dedicated to examine the possibility to apply vanadium complexes with hydrazide-hydrazones for treatment of civilization diseases. Current phase of the project covers diabetes research. Other possible applications of vanadium complexes are diseases such as: cancer, neurodegenerative and cardiovascular diseases.
Additional information (attached documents)
Additional information (attached documents)
About Centre Technology Transfer CITTRU
Technology Transfer Office from PolandCentre Technology Transfer CITTRU
Centre for Innovation, Technology Transfer and University Development (CITTRU) is a part of Jagiellonian University, whose role is to promote university research, to support innovation and to create cooperation with the business. CITTRU main task is to offer the scientific achievements of the Jagiellonian University in the market by providing legal protection, licensing, sale of intellectual property rights, creation of academic business, coordination of company-ordered research projects, etc. Currently promoted technologies are mainly focused on new materials science, pharmacology and medical technology.
Inventions offered by Jagiellonian University are promoted and awarded during numerous exhibitions, e.g. 58th International Exhibition of Innovation, Research and New Technologies INNOVA (BRUSSELS 2009), 38th International Exhibition of Invention New Techniques & Products (Geneva 2010) or 24th International exhibition of environmental equipment, technologies and services POLLUTEC (Paris 2009).